SCHEMBL5146644

SCHEMBL5146644

Cc1cc(C)c(C(=O)C(C(=O)c2c(C)cc(C)cc2C)C(C)(C)P=O)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
HPGD P15428 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
MCOLN3 Q8TDD5 1/20 0.35
TAS1R3 Q7RTX0 3/20 0.33
TAS1R1 Q7RTX1 3/20 0.33
TAS1R2 Q8TE23 3/20 0.33
HTT P42858 2/20 0.33
LMNA P02545 3/20 0.32
KMT2A Q03164 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP9 P14780 1/20 0.32
MMP8 P22894 1/20 0.32
MMP13 P45452 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6470319 0.82 L3MBTL1 (0.37) KDM4EL3MBTL1HPGDKMT2AMEN1
SCHEMBL7178170 0.80 L3MBTL1 (0.37) KDM4EL3MBTL1HPGDNPSR1MCOLN3
SCHEMBL2496206 0.73 HPGD (0.39) KDM4EL3MBTL1HPGDNPSR1MCOLN3
SCHEMBL611536 0.72 KDM4E (0.35) KDM4EL3MBTL1HPGDNPSR1MCOLN3
SCHEMBL2499311 0.72 KDM4E (0.41) KDM4EL3MBTL1HPGDNPSR1MCOLN3
SCHEMBL27976891 0.72 HPGD (0.41) KDM4EL3MBTL1HPGDNPSR1MCOLN3
SCHEMBL10019207 0.70 FFAR1 (0.50) KDM4EL3MBTL1HPGDNPSR1MCOLN3
SCHEMBL6435734 0.69 SLC6A2 (0.42) L3MBTL1HPGDNPSR1MCOLN3HTT
SCHEMBL10320090 0.69 NPSR1 (0.39) KDM4EL3MBTL1HPGDNPSR1MCOLN3
SCHEMBL2499307 0.69 KDM4E (0.36) KDM4EL3MBTL1HPGDNPSR1MCOLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7214830-B2 Process for the preparation of acylphosphines, acyl oxides and acyl sulfides CIBA SPECIALTY CHEMICALS CORPORATION (US) 2007-05-08 US disclosed
US-7094931-B2 Process for the preparation of acylphosphines, acyl oxides and acyl sulfides CIBA SPECIALTY CHEMICALS CORPORATION (US) 2006-08-22 US disclosed
EP-1135399-B2 PROCESS FOR PREPARING ACYLPHOSPHINES AND DERIVATIVES CIBA SC HOLDING AG (CH) 2006-08-09 EP disclosed
US-20060128959-A1 Process for the preparation of acylphosphines, acyl oxides and acyl sulfides IGM GROUP B.V. (NL) 2006-06-15 US disclosed
US-20050096406-A1 Reactive diluents and alkyd resin coating compositions PRETOT ROGER (CH) 2005-05-05 US disclosed
US-20040248855-A1 Process for the preparation of acylphosphines, acyl oxides and acyl sulfides IGM GROUP B.V. (NL) 2004-12-09 US disclosed
EP-1135399-B1 PROCESS FOR PREPARING ACYLPHOSPHINES AND DERIVATIVES CIBA SC HOLDING AG (CH) 2002-08-07 EP disclosed
US-5534559-A UNSATURATED POLYESTERS CIBA-GEIGY CORPORATION (US) 1996-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128959-A1 Process for the preparation of acylphosphines, acyl oxides and acyl sulfides AGPS, PHOSPHO1, AGPAT2 KDM4E 2976/4885L3MBTL1 2313/4885HPGD 2329/4885
US-20040248855-A1 Process for the preparation of acylphosphines, acyl oxides and acyl sulfides AGPS, PHOSPHO1, AGPAT2 KDM4E 3169/4885L3MBTL1 2341/4885HPGD 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.